We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

CELLAVISION AB

Ground-Breaking Test Assesses Expansion and Persistence of CAR-T Therapy in Cancer Patients

By LabMedica International staff writers
Posted on 21 Feb 2023

Chimeric Antigen Receptor T-Cell (CAR-T) therapy is a revolutionary form of immunotherapy that utilizes genetically engineered T-cells to attack cancer cells and has demonstrated promise in treating various types of cancers. Research has shown that the persistence and expansion of CAR-T therapy are important indicators of how long the therapy can remain effective in the patient. Now, a ground-breaking test provides clinicians with an accurate and comprehensive assessment of the CAR-T cell population in the patient's body and offers insights to therapy effectiveness.

Eurofins Viracor LLC (Lenexa, KS, USA) has launched the ExPeCT CAR-T multiplexed quantitative real-time PCR (qPCR) assay that acts as a powerful diagnostic tool to monitor and optimize CAR-T therapy involving patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas. The test, based on a method developed by Eurofins Viracor, is designed to help clinicians better understand how CAR-T therapy is performing for their patients. The test marks an important step forward in the evaluation and management of CAR-T therapy in cancer patients by helping clinicians to make more informed decisions about the best course of treatment for their patients.


Image: ExPeCT CAR-T multiplexed qPCR) assay directly monitors effectiveness of CAR T-cell therapy (Photo courtesy of Eurofins Viracor)
Image: ExPeCT CAR-T multiplexed qPCR) assay directly monitors effectiveness of CAR T-cell therapy (Photo courtesy of Eurofins Viracor)

Related Links:
Eurofins Viracor LLC


New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Automatic Nucleic Acid Extractor
GeneRotex 24

Latest Immunology News

AI Tool Predicts Cancer Patients’ Response to Immunotherapy

Molecular Profiling Improves Diagnosis for Children with High Risk Cancers

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients



LGC Clinical Diagnostics